Efficacy of 3-dimensional conformal radiotherapy in treatment of advanced pancreatic cancer:a report of 30 cases
Yue Jiang
Abstract
Yue Jiang
Abstract
Objective To assess the efficacy and toxicity of 3-dimensional conformal radiotherapy(3DCRT) in treatment of advanced pancreatic cancer.Methods Thirty patients with advanced pancreatic cancer received 3DCRT 50-60 Gy/5-6 weeks,1.8-2 Gy/d,5 fractions per week.Results After radiotherapy,abdominal pain was relieved completely in 21of these 30 patients(70.0%),jaundice disappeared in 19 of these 30 patients(63.3%).Up to the time of reexamination at 1-3 months after radiotherapy,the overall response rate(CR+PR) was 73.2%(22/30).The median survival duration and the 1-year survival rate were 13 months and 55% respectively.The treatment was tolerated well.Grade-I-II leukocytopenia developed in 19 patients(63.3%) and Grade-I-II nausea/vomiting developed in 18 patients(60.0%).Conclusion The study demonstrates that 3DCRT improves symptoms and survival in patients with pancreatic cancer.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To assess the efficacy and toxicity of 3-dimensional conformal radiotherapy(3DCRT) in treatment of advanced pancreatic cancer.Methods Thirty patients with advanced pancreatic cancer received 3DCRT 50-60 Gy/5-6 weeks,1.8-2 Gy/d,5 fractions per week.Results After radiotherapy,abdominal pain was relieved completely in 21of these 30 patients(70.0%),jaundice disappeared in 19 of these 30 patients(63.3%).Up to the time of reexamination at 1-3 months after radiotherapy,the overall response rate(CR+PR) was 73.2%(22/30).The median survival duration and the 1-year survival rate were 13 months and 55% respectively.The treatment was tolerated well.Grade-I-II leukocytopenia developed in 19 patients(63.3%) and Grade-I-II nausea/vomiting developed in 18 patients(60.0%).Conclusion The study demonstrates that 3DCRT improves symptoms and survival in patients with pancreatic cancer.
Key concepts: Medicine, Leukocytopenia, Nausea, Pancreatic cancer, Vomiting, Radiation therapy, Jaundice, Abdominal pain